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A 48 year old female patient presented with severe myalgia and 
dark colored urine for one week. Two days earlier she developed 
sore throat and right fl ank pain. Three weeks prior, patient was 
 diagnosed with hypothyroidism and hypertriglyceridemia and began 
fenofi brate monotherapy 160mg. Laboratory values on admission 
revealed acute renal failure: BUN 87, Cr 4.2. Patient also had trans-
aminitis but an otherwise normal liver function panel: AST 1983, 
ALT 844. Given the patient’s symptomology, our differential diag-
nosis included glomerulonephritis secondary to post-streptococcal 
or IgA nephropathy and rhabdomyolysis. Antistreptolysin O titer and 
rapid streptococcus antigen test were negative. Complement values 
were normal (C3 123, C4 23.9). Rhabdomyolysis best explained the 
doubled AST versus ALT transaminitis. Creatine kinase of 45,510 
and a urinalysis showing a large amount of blood with no red blood 
cells confi rmed diagnosis of rhabdomyolysis. Urine microanalysis 
revealed muddy brown casts consistent with acute tubular necrosis, 
and urine myoglobin was positive. Patient was diagnosed with rhabdomyolysis secondary to fenofi brate. The 
 fenofi brate was stopped, and she responded quickly to aggressive volume resuscitation.
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Introduction
Rhabdomyolysis secondary to fenofi brate monotherapy 
is a rare, recently described event.1 More often 
 described is rhabdomyolysis during statin or statin- 
fi brate combination therapy.1 Based on case report 
 evidence, its incidence is increased in patients with 
hypothyroidism.1,2 Our patient presented in rhabdo-
myolysis, secondary to fenofi brate monotherapy, with 
recently diagnosed hypothyroidism. We suggest 
 identifying hypothyroidism when implementing 
statin or  fi brate therapy and close monitoring  during 
 initiation. Reports of mean days of treatment before 
onset can guide monitoring length: 348 for statin, 
77 for fi brate and 32 for combination therapy.2 These 
incidence rates were greatest within the fi rst six 
months and  after 24 months of treatment; however 
they found no  statistically signifi cant difference in 
 incidence rates over this time period.2 
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Summary Questions
Why is this important? Lipid lowering agents are the most 
 prescribed class of drugs in the United States.8 
How does this risk compare among lipid-lowering agents? Increased risk 
of rhabdomyolysis compared to statin monotherapy is 5.5 fold for fi brate 
mono therapy and 12-fold for combination therapy.2 Among the statins, 
simvastatin, atorvastatin, and pravastatin there was no statistically 
signifi cant difference in incidence.2 
What are the incidence rates of rhabdomyolysis? 
Two large JAMA trials report incidence of rhabdo myolysis during lipid 
lowering therapy. 2,9 
In the A to Z trial, incidence rates of myopathy for 80mg of simvastatin 
was .4%; these 9 cases included 3 of which developed rhabdomyolysis.9 
 This risk is further increased in hypothyroidism: a large cohort study 
showed that 20% of rhabdo myolysis cases during statin or fi brate treatment 
were on thyroid replacement therapy.2 
Pathophysiology
Why is there an increased risk of rhabdomyolysis 
 during fi brate therapy in hypothyroidism? The answer 
may lie in fatty acid oxidation (beta oxidation). 
 Tri glycerides are hydrolyzed into free fatty acids 
and glycerol.3 Fatty acids then enter mitochondria 
and are oxidized into acetyl CoA and converted to 
ATP.3  Hypothyroidism impairs beta oxidation and 
ATP  turnover in myocytes.4 Fatty acid oxidation 
 impairment is also  associated with rhabdomyolysis.5 
 Feno fi brates activate lipoprotein lipase, which hydro-
lyzes triglycerides into fatty acids.6 Thus, adding 
 fenofi brate increases the amount of fatty acids to be 
oxidized and stresses a pathway impaired in hypothy-
roidism and rhabdo myolysis.5,6
Mean Days Of Treatment Before Rhabdomyolysis2
















•  Hypothyroidism affects myocyte mitochondria.  Impaired pro-
cesses include myosin ATPase activity, oxidative metabolism, 
and fatty acid break-down, leading to low ATP turn-over.4 
ATP depletion can be a initiating factor in cell lysis.7 
•  Rhabdomyolysis involves skeletal myocyte lysis  resulting in 
cellular content entering circulation.5 Fatty acid oxidation 
 impairment can predispose  individuals to rhabdomyolysis.5 
One specifi c gene defi ciency implicated is CPT which 
 transfers fatty acids from cytosol to matrix within mitochondria 
for beta oxidation.5 
•  Free fatty acids play a role in causing cell lysis.7 They can act as a 
detergent to membranes and damage mitochondria resulting in leak-
age of  apoptotic  factors.7 Both membrane damage and ATP  depletion 
 decreases activity of Na/K ATPase and Ca membrane pumps leading to intra-
cellular  accumulation of Na and Ca.4,7  Sodium infl ux leads to cellular swelling and calcium infl ux 
leads to  activation of proteolytic  enzymes.7 This has many deleterious effects including leading to 
 release of more free fatty acids.7 This is how free fatty acids, associated with fi brate use, and 
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•  Rhabdomyolysis incidence is increased in 
 hypo thyroidism and fi brate use.4
•  There are pathophysiologic reasons why 
 hypo thyroidism increases risk of rhabdomyolysis 
during  fi brate use. 4,5,7 
•  Since rhabdomyolysis is considered extremely 
rare in absence of statin or fi brate use, screening 
patients for hypothyroidism during initiation  
could powerfully affect the incidence of this life-
threatening adverse effect.1
